EUVIMEDOpdag EUVIMED
Crossref

Time to direct-acting antivirals initiation and liver-related events in people with HIV and Hepatitis C virus.

Mathieu Chalouni, Daniela K van Santen, Juan Berenguer, Inmaculada Jarrín, Miro, José M, Marina B. Klein, Young, Jim, Torgersen, Jessie, Rentsch and 20 more

Open Access CRIS of the University of Bern · 2025-07-01

DOI: 10.48620/86507 ↗

At a glance

Journal article in Open Access CRIS of the University of Bern, published on 2025-07-01. Written by Mathieu Chalouni and 31 co-authors.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objective

People with HIV-HCV co-infection need antiretroviral treatment (ART) to suppress HIV and direct-acting antivirals (DAAs) to cure HCV. ART is typically prioritized, but delays in DAA initiation may increase the risk of liver-related events and HCV transmission to others.

Design

Target trial emulation with observational data collected in routine clinical practice from a collaboration of cohorts from Europe and North America.

Methods

We included DAA-naïve adults with HIV-HCV co-infection who achieved HIV virologic suppression (HIV RNA 6 months) DAA initiation and the 36-month risk of liver-related events (liver decompensation or hepatocellular carcinoma).

Results

Of 862 eligible individuals (median age 46 years; interquartile range 36 to 56), 14% were women, and 52% had a history of injection drug use. The 6 and 36-month probabilities of not initiating DAA were 58% (95% CI: 55, 61) and 24% (21, 27), respectively. The 36-month risk of liver-related events was 1.1% (0.4, 2.0) for early initiation and 1.7% (0.7, 2.5) for delayed initiation; risk difference -0.5% (-1.2, 0.4).

Conclusions

Almost one-quarter of people with HIV-HCV co-infection on ART had not initiated DAA 3 years after HIV virologic suppression. Because the 3-year risk of liver-related events was low, estimates of the impact of delayed DAA initiation were imprecise.

Subjects

HIV/HCV coinfectiondirect-acting antiviralsdelayed treatment initiationliver-related eventshepatocellular carcinomahepatic decompensationantiretroviral therapyHCV cureHCV transmission

Cite

APA

Chalouni, M., Santen, D. K. V., Berenguer, J., Jarrín, I., Miro, M, J., Klein, M. B., Young, Jim, Torgersen, Jessie, Rentsch, T, C., Gill, John, M., Epstein, R. L., Linas, B. P., Zangerle, R., Surial, B., …, & Lodi, S. (2025). Time to direct-acting antivirals initiation and liver-related events in people with HIV and Hepatitis C virus. Open Access CRIS of the University of Bern. https://doi.org/10.48620/86507

Vancouver

Chalouni M, Santen DKV, Berenguer J, Jarrín I, Miro, M J, et al. Time to direct-acting antivirals initiation and liver-related events in people with HIV and Hepatitis C virus. Open Access CRIS of the University of Bern. 2025. doi:10.48620/86507

BibTeX
@article{Chalouni2025,
  author = {Chalouni, Mathieu and Santen, Daniela K van and Berenguer, Juan and Jarrín, Inmaculada and Miro and M, José and Klein, Marina B. and Young and Jim and Torgersen and Jessie and Rentsch and T, Christopher and Gill and John, M and Epstein, Rachel L. and Linas, Benjamin Paul and Zangerle, Robert and Surial, Bernard and Rauch, Andri and Touloumi, Giota and Papadopoulos, Antonios and Wittkop, Linda and Valk, Marc van der and Boyd, Anders C. and Monforte and d'Arminio, Antonella and Puoti, Massimo and Logan, Roger W and Rein, Sophia M. and Hernán, Miguel Ángel and Lodi, Sara},
  title = {Time to direct-acting antivirals initiation and liver-related events in people with HIV and Hepatitis C virus},
  journal = {Open Access CRIS of the University of Bern},
  year = {2025},
  doi = {10.48620/86507}
}
Start for free →